Research recommendations coming out of this guidance What are the clinical features or factors that suggest treatment should be switched or stopped for people with diabetic macular oedema? What are the prognostic factors for the progression of non-proliferative diabetic retinopathy to proliferative diabetic retinopathy, diabetic macular oedema and macular ischaemia? What is the effectiveness and acceptability of observation, anti-vascular endothelial growth factor agents (anti-VEGFs) and laser photocoagulation (alone or in combination) for the treatment of severe non-proliferative diabetic retinopathy? In people experiencing a rapid, substantial reduction in HbA1c, what is the risk of short-term progression of diabetic retinopathy or diabetic macular oedema, and is there a risk of long-term visual loss? What is the effectiveness and acceptability of combination treatments for proliferative diabetic retinopathy?
What are the clinical features or factors that suggest treatment should be switched or stopped for people with diabetic macular oedema?
What are the prognostic factors for the progression of non-proliferative diabetic retinopathy to proliferative diabetic retinopathy, diabetic macular oedema and macular ischaemia?
What is the effectiveness and acceptability of observation, anti-vascular endothelial growth factor agents (anti-VEGFs) and laser photocoagulation (alone or in combination) for the treatment of severe non-proliferative diabetic retinopathy?
In people experiencing a rapid, substantial reduction in HbA1c, what is the risk of short-term progression of diabetic retinopathy or diabetic macular oedema, and is there a risk of long-term visual loss?
What is the effectiveness and acceptability of combination treatments for proliferative diabetic retinopathy?